Dr. Reddy’s Stakes Claim In U.S. OTC Market With Leiner Deal
This article was originally published in The Tan Sheet
Executive Summary
Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products
You may also be interested in...
Leiner Ownership Expected To Change Hands In Recapitalization Deal
North Castle Partners is reportedly in the second round of talks to sell its stake in Leiner Health Products to another private equity firm
Dr. Reddy’s, Leiner Partnership Focusing On Switches
Dr. Reddy's Laboratories and Leiner Health Products are actively looking at potential Rx-to-OTC switch projects as they build on their partnership
Fexofenadine ANDA
Dr. Reddy's Labs has filed ANDA for fexofenadine 30 mg, 60 mg and 180 mg, equivalent to Aventis' Allegra, firm says March 25. Aventis subsequently filed lawsuit in New Jersey federal court alleging patent infringement on six Orange Book patents, Dr. Reddy's notes. Firm will likely switch products in future; Hyderabad, India-based Dr. Reddy's recently sealed distribution deal with Leiner to expand foothold in U.S. OTC drug market (1"The Tan Sheet" March 3, 2003, p. 3)...